Mindmed announces constructive end-of-phase 2 meeting with u.s. fda for mm120 in generalized anxiety disorder (gad)

New york--(business wire)---- $mnmd--mind medicine (mindmed) inc. (nasdaq: mnmd) (the “company” or “mindmed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the end-of-phase 2 (eop2) meeting with the u.s. food and drug administration (fda), supporting the advancement of mm120 (lysergic acid diethylamide [lsd] d-tartrate) into pivotal trials for the treatment of adults with gad. “following a constructive en.
MNMD Ratings Summary
MNMD Quant Ranking